Equities analysts predict that Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) will post $8.12 million in sales for the current quarter, Zacks reports. Two analysts have made estimates for Enanta Pharmaceuticals’ earnings, with the lowest sales estimate coming in at $7.53 million and the highest estimate coming in at $8.70 million. Enanta Pharmaceuticals reported sales of $13.98 million in the same quarter last year, which would suggest a negative year over year growth rate of 41.9%. The company is scheduled to issue its next quarterly earnings results after the market closes on Monday, August 7th.

According to Zacks, analysts expect that Enanta Pharmaceuticals will report full-year sales of $8.12 million for the current financial year, with estimates ranging from $75.36 million to $75.69 million. For the next financial year, analysts forecast that the firm will post sales of $82.63 million per share, with estimates ranging from $80.78 million to $84.48 million. Zacks’ sales calculations are an average based on a survey of analysts that that provide coverage for Enanta Pharmaceuticals.

Enanta Pharmaceuticals (NASDAQ:ENTA) last issued its earnings results on Monday, May 8th. The biotechnology company reported ($0.28) EPS for the quarter, topping the Zacks’ consensus estimate of ($0.38) by $0.10. The business had revenue of $9 million for the quarter, compared to the consensus estimate of $9.19 million. Enanta Pharmaceuticals had a negative net margin of 28.68% and a negative return on equity of 4.94%. The company’s revenue for the quarter was down 30.8% compared to the same quarter last year. During the same period in the prior year, the firm earned ($0.09) EPS.

Several research firms recently commented on ENTA. BidaskClub downgraded shares of Enanta Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Tuesday, July 11th. Zacks Investment Research downgraded shares of Enanta Pharmaceuticals from a “hold” rating to a “sell” rating in a research report on Wednesday, June 21st. JMP Securities upgraded shares of Enanta Pharmaceuticals from a “market perform” rating to an “outperform” rating and set a $40.00 price target for the company in a research report on Tuesday, July 11th. Finally, ValuEngine upgraded shares of Enanta Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Friday, June 2nd. Three analysts have rated the stock with a hold rating and three have assigned a buy rating to the company. The stock has an average rating of “Buy” and an average target price of $30.75.

ILLEGAL ACTIVITY NOTICE: This piece was posted by American Banking News and is the sole property of of American Banking News. If you are viewing this piece on another domain, it was illegally copied and reposted in violation of international trademark and copyright laws. The original version of this piece can be viewed at https://www.americanbankingnews.com/2017/08/07/enanta-pharmaceuticals-inc-enta-expected-to-announce-quarterly-sales-of-8-12-million-2.html.

A number of institutional investors have recently made changes to their positions in ENTA. Mason Street Advisors LLC increased its position in shares of Enanta Pharmaceuticals by 7.0% in the first quarter. Mason Street Advisors LLC now owns 3,249 shares of the biotechnology company’s stock worth $100,000 after buying an additional 212 shares during the last quarter. Municipal Employees Retirement System of Michigan increased its position in shares of Enanta Pharmaceuticals by 3.5% in the second quarter. Municipal Employees Retirement System of Michigan now owns 3,280 shares of the biotechnology company’s stock worth $118,000 after buying an additional 110 shares during the last quarter. SG Americas Securities LLC increased its position in shares of Enanta Pharmaceuticals by 5.8% in the second quarter. SG Americas Securities LLC now owns 4,354 shares of the biotechnology company’s stock worth $157,000 after buying an additional 237 shares during the last quarter. BNP Paribas Arbitrage SA increased its position in shares of Enanta Pharmaceuticals by 62.9% in the second quarter. BNP Paribas Arbitrage SA now owns 4,409 shares of the biotechnology company’s stock worth $159,000 after buying an additional 1,702 shares during the last quarter. Finally, State Board of Administration of Florida Retirement System purchased a new position in shares of Enanta Pharmaceuticals during the fourth quarter worth approximately $204,000. Institutional investors own 65.95% of the company’s stock.

Enanta Pharmaceuticals (NASDAQ ENTA) opened at 38.39 on Monday. Enanta Pharmaceuticals has a 52 week low of $21.00 and a 52 week high of $39.05. The company’s market capitalization is $732.60 million. The firm has a 50-day moving average of $36.29 and a 200-day moving average of $32.18.

Enanta Pharmaceuticals Company Profile

Enanta Pharmaceuticals, Inc is a research and development-focused biotechnology company. The Company uses chemistry-driven approach and drug discovery solutions to create small molecule drugs for the treatment of viral infections and liver diseases. Its research and development programs are focused on three disease targets: non-alcoholic steatohepatitis (NASH)/ primary biliary cholangitis (PBC), respiratory syncytial virus (RSV) and hepatitis B virus (HBV).

Get a free copy of the Zacks research report on Enanta Pharmaceuticals (ENTA)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Enanta Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Enanta Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.